Investment Considerations NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multi-billion dollar unmet needs in central nervous system disorders. The company’s lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression and a patent for this novel … Continue reading “NRx Pharmaceuticals Inc. (NASDAQ: NRXP)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |